I think, first observation, it’s going to play a major role. Major role. But we learn about the treatment. And what we started initially was that it was just about having positive or negative PSMA lesions. Meaning, if you had more than a certain amount of PSMA negative lesions, you would not be a good candidate. More and more, we learned that it’s not only about PSMA positive, negative, but about how positive are you? So that in order to be a good candidate for PSMA lutetium, you need a high level of PSMA expression...
I think, first observation, it’s going to play a major role. Major role. But we learn about the treatment. And what we started initially was that it was just about having positive or negative PSMA lesions. Meaning, if you had more than a certain amount of PSMA negative lesions, you would not be a good candidate. More and more, we learned that it’s not only about PSMA positive, negative, but about how positive are you? So that in order to be a good candidate for PSMA lutetium, you need a high level of PSMA expression. You should not believe that somebody with a weak expression of PSMA will be a good responder. So that I believe is the most important. I think it’s more important than the timing at which you give it. I mean, to me, you should give it when you got that high expression. Maybe it’s in the metastatic or more naive setting. Maybe it’s early CRPC. Maybe it’s late CRPC. That that’s a very important message because it puts the monitoring of these patients by subsequent PSMA PET CT and maybe some quantitative measurement respect as central to the monitoring of these patients so today monitoring patients with metastatic CRPC and even some metastatic hormone naïve with PSMA PET has become central because that’s going to guide the optimal timing of starting your PSMA therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
